MedTrace Logo

Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041

NCT02826382 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-01-12

No results posted yet for this study

Summary

A phase1 study to demonstrate \[68Ga\]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.

Conditions

Interventions

DRUG

[68Ga]P15-041

Imaging by Positron Emission Tomography after injection of \[68Ga\]P15-041

Sponsors & Collaborators

  • Five Eleven Pharma, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-20
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02826382 on ClinicalTrials.gov